Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

Abstract: A 64‐year‐old woman, who had presented with a 30‐year history of refractory asthma, and been treated with anti‐allergic drug therapy, inhaled corticosteroids, a long‐acting beta‐agonist, and a long‐acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.

ePDFPDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: iMedicalApps: This Week's Top Picks for Apple and Android https://t.co/KQgu08Rpzj
1hreplyretweetfavorite
Interasma RT @Aller_MD: HIV vaccine protects non-human primates from infection https://t.co/6b7m7ivwdY
1hreplyretweetfavorite
Interasma RT @Aller_MD: Subfertility linked to increased #asthma risk in offspring https://t.co/pRztkOtpoy
1hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergy, Asthma & Immunology! https://t.co/x6oPcvzlZg #cta_journal #immune
1hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/e71Ef1ORZS Thanks to @EAACI_HQ #cta_journal #immune
1hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma